» Articles » PMID: 36736767

Ribonucleosides from TRNA in Hyperglycemic Mammalian Cells and Diabetic Murine Cardiac Models

Overview
Journal Life Sci
Publisher Elsevier
Date 2023 Feb 3
PMID 36736767
Authors
Affiliations
Soon will be listed here.
Abstract

Aims: Cardiomyopathy is a diabetic comorbidity with few molecular targets. To address this, we evaluated transfer RNA (tRNA) modifications in the diabetic heart because tRNA modifications have been implicated in diabetic etiologies.

Main Methods: tRNA was isolated from aorta, apex, and atrial tissue of healthy and diabetic murine hearts and related hyperglycemic cell models. tRNA modifications and canonical ribonucleosides were quantified by liquid-chromatography tandem mass spectrometry (LC-MS/MS) using stable isotope dilution. Correlations between ribonucleosides and diabetic comorbidity pathology were assessed using statistical analyses.

Key Findings: Total tRNA ribonucleoside levels were analyzed from cell types and healthy and diabetic murine heart tissue. Each heart structure had characteristic ribonucleoside profiles and quantities. Several ribonucleosides were observed as significantly different in hyperglycemic cells and diabetic tissues. In hyperglycemic models, ribonucleosides N-acetylcytidine (acC), 5-methoxycarbonylmethyl-2-thiouridine (mcmsU), 5-methylcytidine (mC), and N-methylguanosine (mG) were anomalous. Specific tRNA modifications known to be on murine tRNA were higher in diabetic heart tissue which suggests that tRNA modifications could be regulating translation in diabetes.

Significance: We identified tRNA ribonucleosides and tRNA species associated with hyperglycemia and diabetic etiology.

Citing Articles

Abnormal ac4C modification in metabolic dysfunction associated steatotic liver cells.

Zhang X, Zheng Y, Yang J, Yang Y, He Q, Xu M Sci Rep. 2025; 15(1):1013.

PMID: 39762452 PMC: 11704021. DOI: 10.1038/s41598-024-84564-0.


The potential of RNA methylation in the treatment of cardiovascular diseases.

Wang K, Wang Y, Li Y, Fang B, Li B, Cheng W iScience. 2024; 27(8):110524.

PMID: 39165846 PMC: 11334793. DOI: 10.1016/j.isci.2024.110524.


Methylation modifications in tRNA and associated disorders: Current research and potential therapeutic targets.

Wu Z, Zhou R, Li B, Cao M, Wang W, Li X Cell Prolif. 2024; 57(9):e13692.

PMID: 38943267 PMC: 11503269. DOI: 10.1111/cpr.13692.


TRIB1 regulates liver regeneration by antagonizing the NRF2-mediated antioxidant response.

Sun X, Wang S, Miao X, Zeng S, Guo Y, Zhou A Cell Death Dis. 2023; 14(6):372.

PMID: 37355685 PMC: 10290656. DOI: 10.1038/s41419-023-05896-9.

References
1.
Boccaletto P, Stefaniak F, Ray A, Cappannini A, Mukherjee S, Purta E . MODOMICS: a database of RNA modification pathways. 2021 update. Nucleic Acids Res. 2021; 50(D1):D231-D235. PMC: 8728126. DOI: 10.1093/nar/gkab1083. View

2.
Zinshteyn B, Gilbert W . Loss of a conserved tRNA anticodon modification perturbs cellular signaling. PLoS Genet. 2013; 9(8):e1003675. PMC: 3731203. DOI: 10.1371/journal.pgen.1003675. View

3.
Low Wang C, Hess C, Hiatt W, Goldfine A . Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation. 2016; 133(24):2459-502. PMC: 4910510. DOI: 10.1161/CIRCULATIONAHA.116.022194. View

4.
Gupta R, Laxman S . tRNA wobble-uridine modifications as amino acid sensors and regulators of cellular metabolic state. Curr Genet. 2019; 66(3):475-480. DOI: 10.1007/s00294-019-01045-y. View

5.
Jia G, Hill M, Sowers J . Diabetic Cardiomyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circ Res. 2018; 122(4):624-638. PMC: 5819359. DOI: 10.1161/CIRCRESAHA.117.311586. View